Rift Biotherapeutics

  • Home
  • Rift Biotherapeutics
SalvaRx led a Series A investment into Rift Biotherapeutics("Rift") in March 2017.  Rift, an early stage research and development company, was founded in 2015 in order to discover and develop first-in-class antibodies to targets implicated in the inflammed state of the tumour microenvironment.  Rift has a small lab space in San Diego, California and has recently won the Boehringer Ingelheim Innovation prize, entitling it to additional lab space at BioLabs San Diego, a Southern California based incubator for biotech start-ups.


The most recent information about Rift Biotherapeutics can be found on its website, riftbio.com

Rift Biotherapeutics Board of Directors and Senior Management

  • Miguel de los Rios, PhD

    Chief Executive Officer and Director

    Miguel A. de los Rios is currently the CEO of RIFT which he founded with Dr. Cory Bentley in 2015.  He was formerly the Vice President, Research and Development of Sevion from 2014-2017. Previously he was the Vice President of Research and Development of Fabrus, Inc. Prior to Fabrus, he founded Chimeros, Inc., a venture-backed biologics therapeutic company in 2003. At Chimeros, he served as both the Chief Executive Officer as well as the Chief Scientific Officer from 2003-2011, and was the inventor of the company’s core technologies. Dr. de los Rios received his PhD in Biophysical Chemistry from the University of California, Santa Barbara. Dr. de los Rios currently advises several start-up biotechnology companies.

  • Ian B Walters, MD, MBA

    CEO and Director of iOx Therapeutics
    Ian B. Walters, M.D., M.B.A., is the Entrepreneur in Residence at Mediqventures and is part-time CMO of Intensity Therapeutics, Inc. Over his 16 year career, he has demonstrated both leadership and expertise in drug development, including the advancement of multiple cancer compounds from research stages through approval.

    Ian specialises in the evaluation, prioritization, and the innovative development of new therapies for the treatment of severe diseases. He has worked at PDL BioPharma, Inc., Millenium Pharmaceuticals, Inc., and Sorrento Therapeutics, Inc., leading corporate development, translational medicine, clinical development and medical affairs.

    Ian spent seven years at Bristol-Myers Squibb, where he managed physicians overseeing the international development of more than eight oncology compounds (including Nivolimab (anti-PD-1), Ipilimumab (anti-CTLA-4), brivanib (anti VEGF/FGF), anti-IGF/IR, VEGFR2 biologic, Elotuzimab (antiCS1), as well as biomarker and companion diagnostic work. He was a core member of Bristol- Myers Squibb’s Strategic Transactions Group evaluating and executing licensing agreements, mergers and acquisitions, clinical collaborations, and the company’s immuno-oncology strategy.

    Before entering the private sector, Ian was a lead investigator at the Rockefeller University and initiated advanced immunology research to understand the mechanism of action of several compounds. Ian received his MD from the Albert Einstein College of Medicine and an MBA from the Wharton School of The University of Pennsylvania.
  • Briggs Morrison, MD


    Briggs W. Morrison, M.D. has been the Chief Executive Officer of Syndax since June 2015. Dr. Morrison currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm, since June 2015. Prior to joining us, he served as Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca plc, a publicly traded company, from January 2012 to June 2015, leading the company’s global, late-stage development organization and serving as a member of the AstraZeneca senior executive team. He previously held a number of positions at Pfizer Inc., a publicly traded company, from 2007 to January 2012 that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business, and also served in roles of increasing responsibility at Merck Research Laboratories, a division of Merck & Co., Inc., from 1995 to 2007, ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. Dr. Morrison was chairman of the board of TransCelerate BioPharma Inc., an industry-funded company charged with improving aspects of clinical trials, from 2014 to 2015, a member of the executive committee of the Clinical Trials Transformation Initiative (CTTI) sponsored by FDA, and is on the board of ACRES (Alliance for Clinical Research Excellence and Safety). Dr. Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut.